Welcome to our dedicated page for Anaptysbio SEC filings (Ticker: ANAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing AnaptysBio’s dense immunology disclosures can feel like decoding a scientific journal. When the annual report 10-K stretches past 300 pages and each 8-K material event carries pipeline-moving details, locating what matters about somatic hyper-mutation spending or milestone revenue is time-consuming.
Stock Titan solves that problem. Our AI-powered summaries turn every AnaptysBio quarterly earnings report 10-Q filing and AnaptysBio insider trading Form 4 transactions into plain-English highlights—no more search-and-scroll. Receive real-time alerts the moment AnaptysBio Form 4 insider transactions real-time hit EDGAR, and let our platform surface context-rich charts that explain R&D burn, cash runway, and collaboration economics. Curious about executive pay? The AI links directly to the AnaptysBio proxy statement executive compensation sections you need.
Here’s what investors gain:
- 10-K simplified – critical risk factors, antibody pipeline updates, and patent positions extracted for quick review (AnaptysBio annual report 10-K simplified).
- 10-Q analysis – quarter-over-quarter shifts in R&D expense and partnership revenue with instant AnaptysBio earnings report filing analysis.
- Form 4 drill-downs – see every AnaptysBio executive stock transactions Form 4 alongside historical price charts.
- 8-K alerts – material trial results or collaboration amendments appear under “AnaptysBio 8-K material events explained”.
Whether you’re understanding AnaptysBio SEC documents with AI for the first time or monitoring repeat insiders, Stock Titan delivers the transparency you need—faster than toggling through EDGAR links.
Morgan Stanley and its subsidiary Morgan Stanley Capital Services LLC filed a Schedule 13G on 08/05/2025 disclosing a combined passive stake of 1,845,002 ANAB shares (6.3 % of outstanding) as of 06/30/2025. The parent company reports shared voting power over 1,841,919 shares and shared dispositive power over 1,845,002 shares; it holds no sole voting or dispositive authority.
The subsidiary individually owns 1,525,502 shares (5.2 %) with fully shared voting and dispositive power. The filing is made under Rule 13d-1(b), classifying Morgan Stanley as a parent holding company/control person (HC, CO) and the subsidiary as a broker-dealer (BD, CO). Both certify the shares were acquired in the ordinary course of business and not for the purpose of influencing control of AnaptysBio.
Director Dennis M. Fenton of AnaptysBio reported a significant insider transaction on June 18, 2025. The filing details:
- Sale of 3,015 shares of Common Stock at $23.97 per share
- Transaction was executed under a Rule 10b5-1 trading plan established on March 22, 2024
- The sale was primarily to satisfy tax obligations related to restricted stock unit vesting on June 15, 2025
- Following the transaction, Fenton retains direct ownership of 4,965 shares
This transaction appears to be a planned sale for tax purposes rather than a discretionary trade, as evidenced by the pre-established 10b5-1 plan. The sale represents a partial liquidation of Fenton's holdings, maintaining a significant ownership position in the company.
Director Hollings Renton of AnaptysBio reported a sale of 3,015 shares of common stock at $23.97 per share on June 18, 2025. Following the transaction, Renton retains direct ownership of 4,965 shares.
Key details of the transaction:
- The sale was executed under a Rule 10b5-1 trading plan established on March 14, 2024
- The shares were sold to cover tax obligations related to the vesting of restricted stock units on June 15, 2025
- Total transaction value: approximately $72,269
This insider transaction represents a routine sale for tax purposes rather than a discretionary trading decision, as it was pre-planned through a 10b5-1 trading plan and specifically tied to RSU vesting obligations.
AnaptysBio (NASDAQ:ANAB) filed a routine Form 144 on June 29, 2025, notifying the SEC of a proposed sale of 3,015 common shares valued at approximately $72,269.55 (about $23.96 per share). The shares were originally received as restricted stock on June 15, 2025 and are expected to be sold around June 18, 2025 through Morgan Stanley Smith Barney. The filer reported no other sales in the past three months and affirmed that no undisclosed material adverse information is known. With 29,380,496 shares outstanding, the proposed sale represents a negligible fraction of total equity and does not indicate any material change to AnaptysBio’s operations or financial condition.
FAQ
What is the current stock price of Anaptysbio (ANAB)?
What is the market cap of Anaptysbio (ANAB)?
